Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, Suganuma N, Hibi Y, Nemoto T, Takahashi S, Yane K, Ioji T, Kojima S, Kaneda H, Sugitani I, Tahara M.
Higashiyama T, et al.
Eur J Cancer. 2022 Sep;173:210-218. doi: 10.1016/j.ejca.2022.06.044. Epub 2022 Aug 3.
Eur J Cancer. 2022.
PMID: 35932627
Clinical Trial.